Cure8 research brief
The study suggests that in some people with IBD who have Candida overgrowth, systemic antifungal therapy (fluconazole) can change gut microbes and metabolites in ways linked to better disease activity over 8 weeks. That points to a possible new adjunctive treatment approach for fungal-associated IBD.
Adults with Crohn's disease or ulcerative colitis, clinicians caring for IBD patients, gastroenterology researchers interested in the microbiome and mycobiome, and patients with suspected or documented Candida overgrowth/oral thrush.
This Nature Medicine abstract reports a prospective observational study testing oral antifungal strategies in 53 adults with mild-to-moderate ulcerative colitis or Crohn's disease. The study compared swish-and-spit nystatin (ORNT) versus systemic fluconazole (GIFT).
Fluconazole — not nystatin — lowered intestinal Candida, increased bacterial diversity, expanded SCFA-producing bacteria, restored anti-inflammatory metabolites, and was associated with improved disease activity scores and lower risk of progression over 8 weeks.
The paper frames these results as proof-of-concept that targeting the gut mycobiome can reshape cross-kingdom microbial networks in IBD and suggests a pathway for antifungal cotreatment in patients with fungal-associated disease features. The available text is an abstract; Cure8 has summarized the study abstract rather than a full peer-reviewed article text.
This is not treatment advice. Patients should not start or stop antifungals based on this abstract; discuss antifungal strategies with your gastroenterology team, who can interpret suitability, safety (including drug interactions), and monitoring needs for individual cases.
This classification and brief are based on the paper abstract (Nature Medicine). The study is a prospective observational study with an 8-week follow-up; the abstract does not replace full peer-reviewed details on safety, longer-term outcomes, or randomized trial evidence. Antifungals have side effects and drug interactions that require clinician review.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Competing interests: The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...
Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...
The study suggests that polyphenols can change gut bacteria and metabolite production differently in people with IBD versus healthy controls, which could matter for designing personalized dietary interventions.
